DexCom (NASDAQ:DXCM) used its 2026 Investor Day to outline a long-range plan centered on new product launches, broader insurance coverage for continuous glucose monitoring, international expansion and margin improvement.
President and Chief Executive Officer Jake Leach said the company’s next phase
Oxford Club's Marc Lichtenfeld identifies three stocks worth selling in May—DexCom, Colgate-Palmolive, and Oracle—and breaks down the risks behind each call.
Mid-cap stocks often strike the right balance between having proven business models and market opportunities that can support $100 billion corporations. Howe...
Quality compounders are flywheels. Said differently, they’re businesses that generate heaps of profits and consistently reinvest them to produce even more pr...
DexCom’s first quarter saw revenue growth driven by new product launches and increased adoption, particularly among people with type 2 diabetes who are not o...
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results topping the market’s revenue expectations, with sales up 15% year on year to $1.19 bil...
The Nasdaq 100 (^NDX) is known for housing some of the most innovative and fastest-growing companies in the market. But not every stock in the index is a win...
Medical device company DexCom (NASDAQ:DXCM) reported Q1 CY2026 results exceeding the market’s revenue expectations, with sales up 15% year on year to $1.19 b...
It’s time to crown a winner: defending champion Emily Flippen faces off against Cinderella challenger Loren Horst in the Market Cap Madness World Championship.
Medical device company DexCom (NASDAQ:DXCM) will be reporting earnings this Thursday after market close. Here’s what investors should know. DexCom beat analy...
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient...
